Abstract
Aim:
Camptothecin is an anticancer drug that acts against a broad spectrum of tumors. The clinical application of camptothecin is limited by its insolubility, instability, and toxicity problems. The aim of this study was to develop and characterize lipid nanoparticles with different lipid cores which can circumvent these problems.
Methods:
Lipid nanoparticles made of Precirol (solid lipid nanoparticles; SLN-P), Compritol (SLN-C), Precirol+squalene (nanostructured lipid carriers; NLC), and squalene (a lipid emulsion; LE) as the lipid core material were prepared. These systems were assessed and compared by evaluating the mean diameter, surface charge, molecular environment, camptothecin release, and cell viability against a melanoma. The safety and storage stability of these systems were also preliminarily examined.
Results:
The particle size ranged from 190 to 310 nm, with the NLC and LE showing the smallest and largest sizes, respectively. The in vitro drug release occurred in a sustained manner in decreasing order as follows: LE>NLC>SLN-P>SLN-C. It was found that varying the type of inner phase had profound effects on cell viability. The SLN-P generally showed higher cytotoxicity than the free control. The treatment of melanomas with the camptothecin-loaded SLN-C and NLC yielded cytotoxicity comparable to that of the free form. The percentage of erythrocyte hemolysis by all nanoparticles was ≤5%, suggesting a good tolerance to lipid nanoparticles.
Conclusion:
The results collectively suggest that the SLN-P may have the potential to serve as a delivery system for parenteral camptothecin administration because of the sustained drug release, strong cytotoxicity, limited hemolysis, and good storage stability.
Similar content being viewed by others
Article PDF
References
Lorence A, Nessler CL . Camptothecin, over four decades of surprising findings. Phytochemistry 2004; 65: 2735–49.
Hatefi A, Amsden B . Camptothecin delivery methods. Pharm Res 2002; 19: 1389–99.
Thomas CJ, Rahier NJ, Hecht SM . Camptothecin: current perspectives. Bioorg Med Chem 2004; 12: 1585–604.
Hung CF, Fang CL, Liao MH, Fang JY . The effect of oil components on the physicochemical properties and drug delivery of emulsions: to-col emulsion versus lipid emulsion. Int J Pharm 2007; 335: 193–202.
Teeranachaideekul V, Müller RH, Junyaprasert VB . Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)—effects of formulation parameters on physicochemical stability. Int J Pharm 2007; 340: 198–206.
Müller RH, Mäder K, Gohla S . Solid lipid nanoparticles (SLN) for controlled drug delivery — a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161–77.
Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S . Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm 2006; 314: 83–9.
Ruckmani K, Sivakumar M, Ganeshkumar PA . Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. JNanosci Nanotechnol 2006; 6: 1991–5.
Adams DJ . The impact of tumor physiology on camptothecin-based drug development. Curr Med Chem Anti-Cancer Agents 2005; 5: 1–13.
Hatefi A, Knight D, Amsden B . A biodegradable injectable thermoplastic for localized camptothecin delivery. J Pharm Sci 2004; 93: 1195–204.
Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ . Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999; 59: 299–307.
Freitas C, Müller RH . Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999; 47: 125–32.
Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, et al. Lipid nanoparticles for skin penetration enhancement—correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005; 110: 151–63.
Lee MK, Lim SJ, Kim CK . Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28: 2137–46.
Jenning V, Thünemann AF, Gohla SH . Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000; 199: 167–77.
Mason TG . New fundamental concepts in emulsion rheology. Curr Opin Colloid Interface Sci 1999; 4: 231–8.
Kim BD, Na K, Choi HK . Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 2005; 24: 199–205.
Wong HL, Bendayan R, Rauth AM, Wu XY Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci 2004; 93: 1993–2008.
Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W . Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorom-etry and Raman spectroscopy. Pharm Res 2005; 22: 1887–97.
Souto EB, Wissing SA, Barbosa CM, Müller RH . Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278: 71–7.
Hansch C, Telzer BR, Zhang L . Comparative QSAR in toxicology: examples from teratology and cancer chemotherapy of aniline mustards. Crit Rev Toxicol 1995; 25: 67–89.
Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ . Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur J Pharm Sci 2002; 15: 163–70.
Wang JJ, Sung KC, Hu OYP, Yeh CH, Fang JY . Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. J Control Release 2006; 115: 140–9.
Westesen K, Bunjes H, Koch MHJ . Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 1997; 48: 223–36.
zur Mühlen A, Schwarz C, Mehnert W . Solid lipid nanoparticles (SLN) for controlled drug delivery – drug release and release mechanism. Eur J Pharm Biopharm 1998; 45: 149–55.
Hou DZ, Xie CS, Huang KJ, Zhu CH . The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 2003; 24: 1781–5.
Lundberg BB . Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. Anti-Cancer Drug Design 1998; 13: 453–61.
Cheung KJ, Li G . The tumor suppressor p33INGl does not enhance camptothecin-induced cell death in melanoma cells. Int J Oncol 2002; 20: 1319–22.
Quotob SS, Ng CE . Comparison of apoptotic, necrotic and clonogen-ic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line. Cancer Chemother Pharmacol 2002; 49: 167–75.
Vasir JK, Reddy MK, Labhasetwar VD . Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005; 1: 47–64.
Tabatt K, Kneuer C, Sameti M, Olbrich C, Müller RH, Lehr C, et al. Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. J Control Release 2004; 97: 321–32.
Asasutjarit R, Lorenzen SI, Sirivichayakul S, Puxrungtham K, Ruk-tanonchai U, Ritthidej GC . Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-Hugag transfection. Pharm Res 2007; 24: 1098–107.
Adams DJ, Dewhirst MW, Flowers JL, Gamcsik MP, Colvin OM, Manikumar G, et al. Camptothecin analogues with enhanced anti-tumor activity at acidic pH. Cancer Chemother Pharmacol 2000; 46: 263–71.
Pongcharoenkiat N, Narsimhan G, Lyons RT, Hem SL . The effect of surface charge and partition coefficient on the chemical stability of solutes in o/w emulsions. J Pharm Sci 2002; 91: 559–70.
Tang CH, Grimm EA . Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 2004; 279: 288–98.
Bjerregaard S, Wulf-Andersen L, Stephens RW, Lund LR, Vermehren C, Söderberg I, et al. Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injections of w/o emulsions incorporating aprotinin. J Control Release 2001; 71: 87–98.
Ahyayauch H, Goni FM, Bennouna M . Interaction of electrically neutral and cationic forms of imipramine with liposome and erythro-cyte membranes. Int J Pharm 2004; 279: 51–8.
Weyenberg W, Filev P, Van den Plas D, Vandervoort J, De Smet K, Sollie P, et al. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm 2007; 337: 291–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, Zr., Hua, Sc., Yang, Yl. et al. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 29, 1094–1102 (2008). https://doi.org/10.1111/j.1745-7254.2008.00829.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00829.x
Keywords
This article is cited by
-
Development and Characterization of Fully Hydrogenated Soybean Oil and High Oleic Sunflower Oil β-carotene Loaded Nanostructured Lipid Carriers
Food Biophysics (2023)
-
Rhein methotrexate-decorated solid lipid nanoparticles altering adjuvant arthritis progression through endoplasmic reticulum stress-mediated apoptosis
Inflammopharmacology (2023)
-
Antibody–drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells
Scientific Reports (2021)
-
SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma
Journal of Materials Science: Materials in Medicine (2021)
-
Lyophilized Hybrid Nanostructured Lipid Carriers to Enhance the Cellular Uptake of Verapamil: Statistical Optimization and In Vitro Evaluation
Nanoscale Research Letters (2018)